[go: up one dir, main page]

AU2418499A - Org-5222 in the treatment of depression - Google Patents

Org-5222 in the treatment of depression

Info

Publication number
AU2418499A
AU2418499A AU24184/99A AU2418499A AU2418499A AU 2418499 A AU2418499 A AU 2418499A AU 24184/99 A AU24184/99 A AU 24184/99A AU 2418499 A AU2418499 A AU 2418499A AU 2418499 A AU2418499 A AU 2418499A
Authority
AU
Australia
Prior art keywords
org
depression
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24184/99A
Inventor
John Stuart Andrews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU2418499A publication Critical patent/AU2418499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU24184/99A 1997-12-19 1998-12-15 Org-5222 in the treatment of depression Abandoned AU2418499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97204026 1997-12-19
EP97204026 1997-12-19
PCT/EP1998/008539 WO1999032108A1 (en) 1997-12-19 1998-12-15 Org-5222 in the treatment of depression

Publications (1)

Publication Number Publication Date
AU2418499A true AU2418499A (en) 1999-07-12

Family

ID=8229089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24184/99A Abandoned AU2418499A (en) 1997-12-19 1998-12-15 Org-5222 in the treatment of depression

Country Status (2)

Country Link
AU (1) AU2418499A (en)
WO (1) WO1999032108A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516000A (en) * 2004-10-15 2008-05-06 Pfizer use of a compound or a pharmaceutically acceptable salt, solvate, hydrate or optical isomer thereof, method for treating bipolar disorder in a mammal in need thereof, and kit for use in treating bipolar disorder
DK1710241T3 (en) 2005-04-07 2010-03-01 Organon Nv Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1h-dibenz [2,3: 6,7] oxepino [4,5-c] pyrrole
GT200600135A (en) * 2005-04-07 2006-11-07 ORTHROMBY CRYSTAL FORM OF ASENAPINE MALEATE AND ITS USE IN THE TREATMENT OF MENTAL DISORDERS
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CA2805542C (en) 2010-07-29 2017-12-12 Laboratorios Lesvi, S.L. Novel process for the preparation of asenapine
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
RU2762896C2 (en) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing asenapine
RU2764443C2 (en) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene
BR112019027037B1 (en) 2017-06-26 2022-04-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer, and process for making an asenapine-containing layer for use in said system
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (en) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178593C (en) * 1974-01-31 1986-04-16 Akzo Nv PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION BASED ON A TETRACYCLIC COMPOUND AND METHOD FOR PREPARING THE TETRACYCLIC COMPOUNDS TO BE USED THEREOF
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5763476A (en) * 1994-03-02 1998-06-09 Akzo Noble N.V. Sublingual or buccal pharmaceutical composition
JP3274579B2 (en) * 1995-01-12 2002-04-15 住友製薬株式会社 Agent for treating psychiatric symptoms associated with cerebrovascular disorders

Also Published As

Publication number Publication date
WO1999032108A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
AUPO203996A0 (en) Therapeutic uses
AU9790198A (en) Compounds and methods
AU9781998A (en) Huchordin and uses thereof
AU2418499A (en) Org-5222 in the treatment of depression
AU2387097A (en) Substituted benzylamines and their use for the treatment of depression
AU8695298A (en) Compounds and uses thereof
AU6300898A (en) Well treatment with particles
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
AU1538499A (en) Body ornament
AU1645599A (en) Human matrilin-3
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU7759698A (en) Hair treatment agents
AU1171099A (en) Therapeutic agents
AU8155898A (en) Human preprotachykinin b
AU8693198A (en) Compounds and uses thereof
AU7583998A (en) Human chemokine zchemo-8
AU2713797A (en) Depigmentating agent in the treatment of melasma
AU2708597A (en) An improvement in the treatment of wastes
AU5386498A (en) Enhancement phalloplasty
AUPO852797A0 (en) Enhancement phalloplasty
AU6409598A (en) An improvement in the treatment of wastes
AU6871798A (en) Human chemokine zsig-35
AU7798198A (en) Non-myeloablative tolerogenic treatment
GB9721978D0 (en) Treatment of depression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase